arrow
A

Amin M. Alousi

md anderson cancer center
H指数:55
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy

供者特异性HLA错配:单倍型与7/8位点错配无关供者造血干细胞移植联合PTCy

2026-06-170
PRE
Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines

急性移植物抗宿主病的临床管理:ASTCT实践指南委员会的循证综述

2026-05-200
OAAI
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes

异基因造血干细胞移植对高风险骨髓增生异常综合征患者的影响

2026-03-270
OAAI
Ex Vivo Mesenchymal Progenitor Cell-based Cord Blood Cell Expansion and Exofucosylation to Enhance Transplant Engraftment

离体间充质祖细胞介导的脐带血细胞扩增及外岩藻糖基化,以增强移植植入效果

2025-11-190
PRE
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

作者更正: 同种异体NK细胞与双特异性先天细胞衔接器治疗难治性复发性淋巴瘤: 1期试验

2025-06-260
PRE
Inflammatory markers and microbiome dysbiosis in hematopoietic cell transplant recipients with lung graft-versus-host disease

炎症标志物和微生物组失调在发生肺部移植物抗宿主病的造血细胞移植受者中的研究

2025-06-010
PRE
Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study

贝卢莫苏迪尔减轻口腔慢性移植物抗宿主病组织炎症和纤维化:一项ROCKstar伴侶研究

2025-05-050
OA
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703

基于移植后环磷酰胺的GVHD预防在70岁及以上患者中的影响:BMT CTN 1703的更新

2025-05-050
OA
Restrictive Ventilatory Defects Following Hematopoietic Stem Cell Transplant Are Associated With Increased Mortality

造血干细胞移植后的限制性通气缺陷与死亡率增加有关

2025-02-010
PRE
Corrigendum to ‘Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation’ [Transplantation and Cellular Therapy 29/3 (2023) 204-204]

更正:‘造血细胞移植后肺功能受损初始检测后的闭塞性细支气管炎综合征风险因素’ [移植与细胞治疗 29/3 (2023) 204-204]

2024-11-170
PRE
Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

异基因造血干细胞移植在CAR T疗法后应用于复发/难治性急性淋巴细胞白血病

BLOOD
IF23.1
2024-11-051
PRE
Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

供者年龄和供-受者性别不匹配对HLA匹配的亲属与非亲属供者造血细胞移植结局的影响

BLOOD
IF23.1
2024-11-050
PRE
Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

供者年龄较轻的半相合造血干细胞移植疗效改善

BLOOD
IF23.1
2024-11-050
PRE
Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

大剂量分次马利兰、氟达拉滨、克拉屈滨、替莫唑胺和维奈克拉(Cladillac)预处理方案用于极高危AML/MDS:一项Ⅱ期临床试验

BLOOD
IF23.1
2024-11-050
PRE
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
2024-09-196
PRE
Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience
2024-06-011
PRE